Intranasal erythropoietin therapy in nervous system disorders

Bibliography

• Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252:5558-64
   PubMed Web of Science ®Google Scholar
• Jacobs K, Shoemaker C, Rudersdorf R, Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-10
   PubMed Web of Science ®Google Scholar
• Lin FK, Suggs S, Lin CH, Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-4
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007;78:183-205
   PubMed Web of Science ®Google Scholar
• Winearls CG, Oliver DO, Pippard MJ, Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8
   PubMed Web of Science ®Google Scholar
• Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484-94
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F, Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12
   PubMed Web of Science ®Google Scholar
• Sanchez PE, Fares RP, Risso JJ, Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci USA 2009;106:9848-53
   PubMed Web of Science ®Google Scholar
• Chen ZY, Warin R, Noguchi CT. Erythropoietin and normal brain development: receptor expression determines multi-tissue response. Neurodegener Dis 2006;3:68-75
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Degner D, Meller J, Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004;9:42-54
   PubMed Web of Science ®Google Scholar
• Siren AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009;6:108-27
   PubMed Web of Science ®Google Scholar
• Digicaylioglu M. Erythropoietin in stroke: quo vadis. Expert Opin Biol Ther 2010;10:937-49
   PubMed Web of Science ®Google Scholar
• Jerndal M, Forsberg K, Sena ES, A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 2010;30:961-8
   PubMed Web of Science ®Google Scholar
• McPherson RJ, Juul SE. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr 2010;22:139-45
   PubMed Web of Science ®Google Scholar
• Minnerup J, Heidrich J, Rogalewski A, The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009;40:3113-20
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol 2007;62:521-4
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord 2008;23:1940-4
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hinze-Selch D, Stawicki S, Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007;12:206-20
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Fischer B, Norra C, Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007;130:2577-88
   PubMed Web of Science ®Google Scholar
• Fauchere JC, Dame C, Vonthein R, An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122:375-82
   PubMed Web of Science ®Google Scholar
• Juul SE, McPherson RJ, Bauer LA, A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122:383-91
   PubMed Web of Science ®Google Scholar
• Springborg JB, Moller C, Gideon P, Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir 2007;149:1089-101
   PubMed Web of Science ®Google Scholar
• Tseng MY, Hutchinson PJ, Richards HK, Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009;111:171-80
   PubMed Web of Science ®Google Scholar
• Zhu C, Kang W, Xu F, Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009;124:218-26
   PubMedGoogle Scholar
• Bernaudin M, Marti HH, Roussel S, A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:643-51
   PubMed Web of Science ®Google Scholar
• Genc S, Kuralay F, Genc K, Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci Lett 2001;298:139-41
   PubMed Web of Science ®Google Scholar
• Sakanaka M, Wen TC, Matsuda S, In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-40
   PubMed Web of Science ®Google Scholar
• Banks WA, Jumbe NL, Farrell CL, Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 2004;505:93-101
   PubMed Web of Science ®Google Scholar
• Brines ML, Ghezzi P, Keenan S, Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C, Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505
   PubMed Web of Science ®Google Scholar
• Xenocostas A, Cheung WK, Farrell F, The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005;61:189-95
   PubMed Web of Science ®Google Scholar
• Chang ZY, Chiang CH, Lu DW, Yeh MK. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection. Expert Opin Drug Deliv 2008;5:1313-21
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5
   PubMed Web of Science ®Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18
   PubMed Web of Science ®Google Scholar
• Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 1998;5:415-41
   PubMed Web of Science ®Google Scholar
• Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv 2008;5:1159-68
   PubMed Web of Science ®Google Scholar
• Thorne RG, Frey WH II. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001;40:907-46
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-96
   PubMed Web of Science ®Google Scholar
• Thorne RG, Hanson LR, Ross TM, Delivery of interferon-b to the monkey nervous system following intranasal administration. Neuroscience 2008;152:785-97
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146-57
   PubMed Web of Science ®Google Scholar
• Li Y, Field PM, Raisman G. Olfactory ensheathing cells and olfactory nerve fibroblasts maintain continuous open channels for regrowth of olfactory nerve fibres. Glia 2005;52:245-51
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Yamashita Y, Mirek H, The ‘perivascular pump’ driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006;14:69-78
   PubMed Web of Science ®Google Scholar
• Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009;117:1-14
   PubMed Web of Science ®Google Scholar
• Born J, Lange T, Kern W, Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514-16
   PubMed Web of Science ®Google Scholar
• Yu YP, Xu QQ, Zhang Q, Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005;387:5-10
   PubMed Web of Science ®Google Scholar
• Gross EA, Swenberg JA, Fields S, Popp JA. Comparative morphometry of the nasal cavity in rats and mice. J Anat 1982;135:83-8
   PubMed Web of Science ®Google Scholar
• Hallschmid M, Benedict C, Schultes B, Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008;149:79-83
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440-8
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005;94:1187-95
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Frey WH II, Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27:451-8
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez JC, Sosa-Teste I. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. Sci World J 2009;9:970-81
   Web of Science ®Google Scholar
• Fletcher L, Kohli S, Sprague SM, Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J Neurosurg 2009;111:164-70
   PubMed Web of Science ®Google Scholar
• Guan J, Beilharz EJ, Skinner SJ, Intracerebral transportation and cellular localisation of insulin-like growth factor-1 following central administration to rats with hypoxic-ischemic brain injury. Brain Res 2000;853:163-73
   PubMed Web of Science ®Google Scholar
• Lin S, Fan LW, Rhodes PG, Cai Z. Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 2009;217:361-70
   PubMed Web of Science ®Google Scholar
• Balin BJ, Broadwell RD, Salcman M, el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986;251:260-80
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Gray AJ, Hirata-Fukae C, Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007;31:165-70
   PubMed Web of Science ®Google Scholar
• Macdonald K, Macdonald TM. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 2010;18:1-21
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Weissenborn K, Prange H, EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:647-56
   PubMed Web of Science ®Google Scholar
• Rasmussen P, Foged EM, Krogh-Madsen R, Effects of erythropoietin administration on cerebral metabolism and exercise capacity in men. J Appl Physiol 2010;109(2):476-83
   PubMed Web of Science ®Google Scholar
• Banks WA, Erickson MA. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 2010;37:26-32
   PubMed Web of Science ®Google Scholar
• Fisher M, Feuerstein G, Howells DW, STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-50
   PubMed Web of Science ®Google Scholar
• Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 2009;40:577-81
   PubMed Web of Science ®Google Scholar
• Minnerup J, Wersching H, Schabitz WR. EPO for stroke therapy – Is there a future for further clinical development? Exp Transl Stroke Med 2010;2:10
   PubMedGoogle Scholar
• Zechariah A, Elali A, Hermann DM. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke 2010;41:1008-12
   PubMed Web of Science ®Google Scholar
• Jia L, Chopp M, Zhang L, Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke 2010; PMID: 20671252. DOI: 10.1161/STROKEAHA.110.586198
   PubMed Web of Science ®Google Scholar
• Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents–time for a reevaluation. N Engl J Med 2010;362:189-92
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
   PubMed Web of Science ®Google Scholar
• Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010;31(2):53-9
   PubMed Web of Science ®Google Scholar
• Esmon CT, Glass JD. The APCs of neuroprotection. J Clin Invest 2009;119:3205-7
   PubMed Web of Science ®Google Scholar
• Erbayraktar S, Grasso G, Sfacteria A, Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003;100:6741-6
   PubMed Web of Science ®Google Scholar
• Masuda S, Okano M, Yamagishi K, A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994;269:19488-93
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G, Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang ZG, Rhodes K, Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007;151:1377-84
   PubMed Web of Science ®Google Scholar
• Brines M, Patel NS, Villa P, Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008;105:10925-30
   PubMed Web of Science ®Google Scholar
• Pankratova S, Kiryushko D, Sonn K, Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain 2010;133:2281-94
   PubMed Web of Science ®Google Scholar
• Shimoda N, Maitani Y, Machida Y, Nagai T. Effects of dose, pH and osmolarity on intranasal absorption of recombinant human erythropoietin in rats. Biol Pharm Bull 1995;18:734-9
   PubMed Web of Science ®Google Scholar
• Alcala-Barraza SR, Lee MS, Hanson LR, Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 2010;18:179-90
   PubMed Web of Science ®Google Scholar
• Hermann DM. Enhancing the delivery of erythropoietin and its variants into the ischemic brain. Sci World J 2009;9:967-9
   Google Scholar
• Sosa I, Garcia Rodriguez JC, Santana J, Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacologyonline 2006;1:100-12
   Google Scholar
• Miskowiak KW, Favaron E, Hafizi S, Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology 2009;207:133-42
   PubMed Web of Science ®Google Scholar
• Miskowiak KW, Favaron E, Hafizi S, Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology 2010;210:419-28
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia F, Krueger JM. Intracerebroventricular injection of erythropoietin enhances sleep in the rat. Brain Res Bull 2003;61:541-6
   PubMed Web of Science ®Google Scholar
• Lagarto A, Bueno V, Guerra I, Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid. Exp Toxicol Pathol 2010; PMID: 20488687. DOI: 10.1016/j.etp.2010.04.008
   Web of Science ®Google Scholar
• Cao Y, Lathia JD, Eyler CE, Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer 2010;1:50-61
   PubMedGoogle Scholar
• Nico B, Annese T, Guidolin D, Epo is involved in angiogenesis in human glioma. J Neurooncol 2010; PMID: 20614229. DOI: 10.1007/s11060-010-0294-6
   Google Scholar
• Cramer SC, Fitzpatrick C, Warren M, The beta-hCG+erythropoietin in acute stroke (BETAS) study: a 3-center, single-dose, open-label, noncontrolled, phase IIa safety trial. Stroke 2010;41(5):927-31
   PubMed Web of Science ®Google Scholar
• Kang YJ, Digicaylioglu M, Russo R, Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann Neurol 2010;68(3):342-52
   PubMed Web of Science ®Google Scholar